Chugai Slides After Ending Trials for Muscle Disorder Drug

Chugai Pharmaceutical said it has ended development of an experimental drug for diseases that cause muscle weakness, and shares fell 7.3% intraday — the largest single-day decline since August 2025. The program shutdown removes a pipeline asset and likely reduces near-term upside for the company's R&D-driven valuation, increasing investor scrutiny and downside risk to the stock.

Analysis

Chugai Pharmaceutical said it has ended development of an experimental drug for diseases that cause muscle weakness, and shares fell 7.3% intraday — the largest single-day decline since August 2025. The program shutdown removes a pipeline asset and likely reduces near-term upside for the company's R&D-driven valuation, increasing investor scrutiny and downside risk to the stock.